
51 - 200 employees
🏭 Manufacturing
📦 Logistics
🧬 Biotechnology
💰 $90M Series A on 2023-12
Manufacturing • Logistics • Biotechnology
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Their unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute their therapies.
Selected: 🇺🇸 United States – Remote USA.
Selected: 🆕 Date Added.
🕒 October 5
Senior Director leading FDA interactions and regulatory submissions for ARTBIO’s clinical-stage cancer radiopharmaceutical programs. Coordinating medical writing, cross-functional deliverables, and compliant submission execution.
🕒 September 8
Head of Regulatory Affairs leading global regulatory strategy and submissions for ARTBIO’s clinical-stage radiopharmaceutical cancer therapies. Advising health-authority engagement and regulatory risk management.